Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02406677
Other study ID # D5130R00030
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 5, 2015
Est. completion date October 23, 2017

Study information

Verified date September 2019
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year. We hypothesize that reducing out--of--pocket cost for P2Y12 receptor inhibitor will lead to improved adherence. Additionally, copayment reduction of both generic and brand antiplatelet agents may lead to a reduction in MACE risk. This is in part due to greater adherence to an evidence--based secondary prevention medication. Additionally the reduction in MACE may reflect greater selection of a more potent antiplatelet agent that has been shown to reduce MACE in randomized clinical trials, as provider choice of antiplatelet therapy will be primarily driven by risk- benefit assessment rather than the cost burden to the patient.


Description:

ARTEMIS is a prospective, cluster-randomized clinical trial that will evaluate whether patient copayment elimination significantly influences antiplatelet therapy selection and long-term adherence, as well as patient outcomes and overall cost of care after acute myocardial infarction. Approximately 11,000 patients with ST-elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) will be enrolled at the approximately 300 hospitals in this study. Study sites selected for ARTEMIS will be geographically diverse, and will represent a diversity of hospital types and capabilities (e.g., teaching hospital, community hospital, etc). After institutional review board (IRB) approval of the study, each hospital will be randomized into either the intervention arm or the control arm. Hospitals randomized to the intervention arm will have the opportunity to offer enrolled patients either clopidogrel (generic P2Y12 receptor inhibitor option) or ticagrelor (brand P2Y12 receptor inhibitor option) without patient contribution to copayment in the next 12 months after the index MI discharge. Hospitals in the control arm will provide care per usual clinical routine. Notably, for both intervention and control arms, all patient management decisions (including the choice of antiplatelet therapy) are completely at the discretion of the care providers. Duration of antiplatelet therapy will also be at the discretion of care providers. All enrolled patients will be followed up to 15 months after index MI discharge to collect data on longitudinal treatment patterns and outcomes. Primary and secondary endpoints will be assessed at 12 months. An additional three months of follow up will assess for antiplatelet persistence and clinical events after discontinuation of the copayment intervention. Centralized follow-up will be conducted every 3 months via telephone or web-based contact.


Recruitment information / eligibility

Status Completed
Enrollment 11001
Est. completion date October 23, 2017
Est. primary completion date October 23, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria:

Patients are eligible to be included in the study if they meet all of the following criteria:

- are = 18 years of age

- have been diagnosed with STEMI or NSTEMI during the index hospitalization

- be treated with a P2Y12 receptor inhibitor at the time of enrollment

- have U.S. based health insurance coverage with prescription drug benefit

- have been fully informed and are able to provide written consent for longitudinal follow-up

Exclusion Criteria:

Patients are excluded if they meet any of the following criteria:

- have a history of prior intracranial hemorrhage

- have any contraindications to P2Y12 receptor inhibitor therapy at discharge

- involvement in another research study that specifies the type and duration of P2Y12 receptor inhibitor use within the next 12 months.

- have a life expectancy of less than one year

- have plans to move outside the US in the next year

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Study voucher card
Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor

Locations

Country Name City State
Puerto Rico Research Site Caguas
United States Research Site Abington Pennsylvania
United States Research Site Albany New York
United States Research Site Alexandria Louisiana
United States Research Site Allentown Pennsylvania
United States Research Site Alpena Michigan
United States Research Site Anchorage Alaska
United States Research Site Anderson South Carolina
United States Research Site Ann Arbor Michigan
United States Research Site Annapolis Maryland
United States Research Site Asheville North Carolina
United States Research Site Athens Georgia
United States Research Site Atlanta Georgia
United States Research Site Atlanta Georgia
United States Research Site Augusta Georgia
United States Research Site Aurora Illinois
United States Research Site Aurora Colorado
United States Research Site Aurora Colorado
United States Research Site Baltimore Maryland
United States Research Site Baltimore Maryland
United States Research Site Bay City Michigan
United States Research Site Belleville Illinois
United States Research Site Bend Oregon
United States Research Site Bethesda Maryland
United States Research Site Billings Montana
United States Research Site Birmingham Alabama
United States Research Site Bloomington Indiana
United States Research Site Bossier City Louisiana
United States Research Site Boston Massachusetts
United States Research Site Boston Massachusetts
United States Research Site Boynton Beach Florida
United States Research Site Bradenton Florida
United States Research Site Bradenton Florida
United States Research Site Bridgeport Connecticut
United States Research Site Bridgeton Missouri
United States Research Site Bridgewater New Jersey
United States Research Site Brighton Massachusetts
United States Research Site Burlington Vermont
United States Research Site Camp Hill Pennsylvania
United States Research Site Canton Ohio
United States Research Site Chambersburg Pennsylvania
United States Research Site Charleston South Carolina
United States Research Site Charleston South Carolina
United States Research Site Charlottesville Virginia
United States Research Site Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Cincinnati Ohio
United States Research Site Cleveland Ohio
United States Research Site Clinton Maryland
United States Research Site Coeur d'Alene Idaho
United States Research Site Colorado Springs Colorado
United States Research Site Columbia Maryland
United States Research Site Columbia South Carolina
United States Research Site Columbia South Carolina
United States Research Site Cooperstown New York
United States Research Site Cottonwood Arizona
United States Research Site Cumming Georgia
United States Research Site Dallas Texas
United States Research Site Danbury Connecticut
United States Research Site Danville Pennsylvania
United States Research Site Davenport Iowa
United States Research Site Dayton Ohio
United States Research Site Daytona Beach Florida
United States Research Site Denver Colorado
United States Research Site Detroit Michigan
United States Research Site Detroit Michigan
United States Research Site Doylestown Pennsylvania
United States Research Site Duluth Minnesota
United States Research Site Durham North Carolina
United States Research Site Englewood Indiana
United States Research Site Escondido California
United States Research Site Fayetteville Arkansas
United States Research Site Fenton Missouri
United States Research Site Flagstaff Arizona
United States Research Site Flemington New Jersey
United States Research Site Flint Michigan
United States Research Site Fort Smith Arkansas
United States Research Site Gainesville Florida
United States Research Site Gastonia North Carolina
United States Research Site Grand Blanc Michigan
United States Research Site Grand Forks North Dakota
United States Research Site Grand Rapids Michigan
United States Research Site Green Bay Wisconsin
United States Research Site Greenwood South Carolina
United States Research Site Haddon Heights New Jersey
United States Research Site Haddon Heights New Jersey
United States Research Site Hattiesburg Mississippi
United States Research Site High Point North Carolina
United States Research Site Hollywood Florida
United States Research Site Honolulu Hawaii
United States Research Site Houston Texas
United States Research Site Houston Texas
United States Research Site Hudson Florida
United States Research Site Huntington Beach California
United States Research Site Huntsville Alabama
United States Research Site Hyannis Massachusetts
United States Research Site Indianapolis Indiana
United States Research Site Indianapolis Indiana
United States Research Site Indianapolis Indiana
United States Research Site Iowa City Iowa
United States Research Site Jackson Michigan
United States Research Site Jackson Tennessee
United States Research Site Jacksonville Florida
United States Research Site Jacksonville Florida
United States Research Site Jacksonville Florida
United States Research Site Jacksonville Florida
United States Research Site Jacksonville Beach Florida
United States Research Site Johnson City New York
United States Research Site Joliet Illinois
United States Research Site Jonesboro Arkansas
United States Research Site Joplin Missouri
United States Research Site Kansas City Missouri
United States Research Site Kansas City Missouri
United States Research Site Kettering Ohio
United States Research Site Knoxville Tennessee
United States Research Site La Crosse Wisconsin
United States Research Site Lakeland Florida
United States Research Site Lancaster Pennsylvania
United States Research Site Largo Florida
United States Research Site Las Vegas Nevada
United States Research Site Lawrenceville Georgia
United States Research Site Lexington Kentucky
United States Research Site Lincoln Nebraska
United States Research Site Lincoln Nebraska
United States Research Site Little Rock Arkansas
United States Research Site Loma Linda California
United States Research Site Los Angeles California
United States Research Site Los Angeles California
United States Research Site Louisville Kentucky
United States Research Site Louisville Kentucky
United States Research Site Louisville Kentucky
United States Research Site Lumberton North Carolina
United States Research Site Lynchburg Virginia
United States Research Site Macon Georgia
United States Research Site Macon Georgia
United States Research Site Marietta Georgia
United States Research Site Marquette Michigan
United States Research Site Memphis Tennessee
United States Research Site Memphis Tennessee
United States Research Site Miami Florida
United States Research Site Middleburg Heights Ohio
United States Research Site Milwaukee Wisconsin
United States Research Site Milwaukee Wisconsin
United States Research Site Milwaukee Wisconsin
United States Research Site Minneapolis Minnesota
United States Research Site Mobile Alabama
United States Research Site Mobile Alabama
United States Research Site Moorestown New Jersey
United States Research Site Morehead City North Carolina
United States Research Site Morgantown West Virginia
United States Research Site Mount Clemens Michigan
United States Research Site Muncie Indiana
United States Research Site Munster Indiana
United States Research Site New Braunfels Texas
United States Research Site New Haven Connecticut
United States Research Site New Orleans Louisiana
United States Research Site New York New York
United States Research Site Newark New Jersey
United States Research Site Norfolk Virginia
United States Research Site North Kansas City Missouri
United States Research Site Northridge California
United States Research Site Oak Ridge Tennessee
United States Research Site Ocala Florida
United States Research Site Oklahoma City Oklahoma
United States Research Site Oklahoma City Oklahoma
United States Research Site Omaha Nebraska
United States Research Site Omaha Nebraska
United States Research Site Omaha Nebraska
United States Research Site Orlando Florida
United States Research Site Overland Park Kansas
United States Research Site Palestine Texas
United States Research Site Panama City Florida
United States Research Site Pasadena California
United States Research Site Paterson New Jersey
United States Research Site Pensacola Florida
United States Research Site Pensacola Florida
United States Research Site Peoria Illinois
United States Research Site Petoskey Michigan
United States Research Site Philadelphia Pennsylvania
United States Research Site Phoenix Arizona
United States Research Site Pinehurst North Carolina
United States Research Site Pittsburgh Pennsylvania
United States Research Site Pittsburgh Pennsylvania
United States Research Site Plano Texas
United States Research Site Pomona New Jersey
United States Research Site Pontiac Michigan
United States Research Site Portland Oregon
United States Research Site Poughkeepsie New York
United States Research Site Puyallup Washington
United States Research Site Racine Wisconsin
United States Research Site Raleigh North Carolina
United States Research Site Raleigh North Carolina
United States Research Site Rapid City South Dakota
United States Research Site Reno Nevada
United States Research Site Reno Nevada
United States Research Site Renton Washington
United States Research Site Richmond Virginia
United States Research Site Richmond Indiana
United States Research Site Ridgewood New Jersey
United States Research Site Riverside California
United States Research Site Roanoke Virginia
United States Research Site Rochester New York
United States Research Site Rockford Illinois
United States Research Site Rockford Illinois
United States Research Site Rockport Maine
United States Research Site Rockville Maryland
United States Research Site Round Rock Texas
United States Research Site Safety Harbor Florida
United States Research Site Saginaw Michigan
United States Research Site Saint Charles Missouri
United States Research Site Saint Cloud Minnesota
United States Research Site Saint Joseph Michigan
United States Research Site Saint Louis Missouri
United States Research Site Saint Louis Missouri
United States Research Site Saint Louis Missouri
United States Research Site Saint Louis Missouri
United States Research Site Saint Louis Missouri
United States Research Site Saint Louis Missouri
United States Research Site Saint Paul Minnesota
United States Research Site Saint Paul Minnesota
United States Research Site Saint Petersburg Florida
United States Research Site Saint Petersburg Florida
United States Research Site Saint Petersburg Florida
United States Research Site Salinas California
United States Research Site Salisbury Maryland
United States Research Site San Antonio Texas
United States Research Site Sarasota Florida
United States Research Site Sayre Pennsylvania
United States Research Site Schenectady New York
United States Research Site Scranton Pennsylvania
United States Research Site Sellersville Pennsylvania
United States Research Site Shreveport Louisiana
United States Research Site South Bend Indiana
United States Research Site Southfield Michigan
United States Research Site Spokane Washington
United States Research Site Springfield Illinois
United States Research Site Stamford Connecticut
United States Research Site Staten Island New York
United States Research Site Stockton California
United States Research Site Stony Brook New York
United States Research Site Suwanee Georgia
United States Research Site Tallahassee Florida
United States Research Site Tampa Florida
United States Research Site Tampa Florida
United States Research Site Teaneck New Jersey
United States Research Site Temple Texas
United States Research Site Thousand Oaks California
United States Research Site Toledo Ohio
United States Research Site Torrance California
United States Research Site Tualatin Oregon
United States Research Site Urbana Illinois
United States Research Site Utica New York
United States Research Site Valhalla New York
United States Research Site Valparaiso Indiana
United States Research Site Vista California
United States Research Site Voorhees New Jersey
United States Research Site Waco Texas
United States Research Site Warren Michigan
United States Research Site Warwick Rhode Island
United States Research Site Waukesha Wisconsin
United States Research Site Webster Texas
United States Research Site West Columbia South Carolina
United States Research Site West Des Moines Iowa
United States Research Site West Reading Pennsylvania
United States Research Site Wilkes-Barre Pennsylvania
United States Research Site Wilmington North Carolina
United States Research Site Winchester Virginia
United States Research Site Winston-Salem North Carolina
United States Research Site Winter Haven Florida
United States Research Site Worcester Massachusetts
United States Research Site York Pennsylvania
United States Research Site York Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Duke Clinical Research Institute

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Kaplan-Meier Cumulative Incidence Rate of Major Adverse Cardiovascular Events To determine if patient copayment reduction leads to lower risk of MACE (composite of death, MI, and stroke) at 1 year after discharge. 12 months
Primary Percentage of Patients With Long Term Non-persistence to P2Y12 Receptor Inhibitor To determine if patient copayment reduction leads to higher long-term persistence of any P2Y12 receptor inhibitor at 1 year after discharge. 12 months
Secondary P2Y12 Receptor Inhibitor Selection To evaluate whether reducing patient copayments for both generic and brand P2Y12 receptor inhibitor options affects medication selection at discharge. 12 months